BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
Read original at benzingaStocks · News reference
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 10:46 PM
- Checked
- Aug 27, 2026, 10:46 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BioNTech shaes are trading lower after the company announced it will terminate its Phase 2 BNT122-01 trial.
Read original at benzingaBioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals
https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/a991260828_bntxxcrcxenxfin.htm
Read original at benzingaWorld Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
Read original at benzingaThis Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Wall Street analysts upgraded Moderna Inc and Evolution Petroleum Corp, and raised Enbridge's price target. Check out analysts' views on MRNA stock.
Read original at benzingaModerna shares are trading lower after the company announced the pricing of its upsized $2.6 billion offering of Convertible Senior Notes.
Read original at benzinga